ZA202309456B - Composition comprising an ige antibody - Google Patents

Composition comprising an ige antibody

Info

Publication number
ZA202309456B
ZA202309456B ZA2023/09456A ZA202309456A ZA202309456B ZA 202309456 B ZA202309456 B ZA 202309456B ZA 2023/09456 A ZA2023/09456 A ZA 2023/09456A ZA 202309456 A ZA202309456 A ZA 202309456A ZA 202309456 B ZA202309456 B ZA 202309456B
Authority
ZA
South Africa
Prior art keywords
composition
ige antibody
ige
antibody
Prior art date
Application number
ZA2023/09456A
Other languages
English (en)
Inventor
Spicer James
Karagiannis Sophia
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/060749 external-priority patent/WO2021214329A1/en
Priority claimed from GBGB2109550.0A external-priority patent/GB202109550D0/en
Application filed by King S College London filed Critical King S College London
Publication of ZA202309456B publication Critical patent/ZA202309456B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA2023/09456A 2021-04-23 2023-10-10 Composition comprising an ige antibody ZA202309456B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
GBGB2109550.0A GB202109550D0 (en) 2021-07-01 2021-07-01 Composition
PCT/EP2022/060693 WO2022223784A1 (en) 2021-04-23 2022-04-22 Composition comprising an ige antibody

Publications (1)

Publication Number Publication Date
ZA202309456B true ZA202309456B (en) 2025-03-26

Family

ID=81750377

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/09456A ZA202309456B (en) 2021-04-23 2023-10-10 Composition comprising an ige antibody

Country Status (10)

Country Link
US (1) US20240190955A1 (https=)
EP (1) EP4326770A1 (https=)
JP (1) JP2024514935A (https=)
KR (1) KR20240001136A (https=)
AU (1) AU2022263376A1 (https=)
BR (1) BR112023021873A2 (https=)
CA (1) CA3215850A1 (https=)
MX (1) MX2023012557A (https=)
WO (1) WO2022223784A1 (https=)
ZA (1) ZA202309456B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CA2848842C (en) 2011-10-04 2020-09-29 King's College London Ige anti -hmw-maa antibody
RU2019141270A (ru) 2017-05-16 2021-06-16 Иммуноджен, Инк. Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
GB202006093D0 (en) * 2020-04-24 2020-06-10 King S College London Composition

Also Published As

Publication number Publication date
EP4326770A1 (en) 2024-02-28
AU2022263376A9 (en) 2023-11-30
MX2023012557A (es) 2023-11-08
CA3215850A1 (en) 2022-10-27
WO2022223784A1 (en) 2022-10-27
AU2022263376A1 (en) 2023-11-23
JP2024514935A (ja) 2024-04-03
BR112023021873A2 (pt) 2023-12-19
US20240190955A1 (en) 2024-06-13
KR20240001136A (ko) 2024-01-03

Similar Documents

Publication Publication Date Title
IL287035A (en) Anti-ige antibodies
IL291246A (en) Anti-cd39 antibody preparations and methods
EP4008730A4 (en) BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
SG11202100888WA (en) Anti-avb8 antibodies and compositions and uses thereof
IL289585A (en) DLL3-targeted antibodies and uses thereof
CA3265597A1 (en) Anti-lilrb1 antibody and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL286100A (en) Formulations of anti-il-36r antibodies
IL291131A (en) Formulations of anti-il-23p19 antibodies
IL289656A (en) Anti-tigit antibodies and their application
ZA202108836B (en) Anti-epha4 antibody
PL3932949T3 (pl) Przeciwciało anty-cd25 i jego zastosowanie
GB2596411B (en) Compositions and methods comprising IgA antibody constructs
IL308695A (en) Anti-NKG2A antibodies and compositions
GB202015115D0 (en) ZIP12 Antibody
EP3858994A4 (en) ANTIBODY COMPOSITION
GB202105933D0 (en) Anti-IL1rap antibody
ZA202309456B (en) Composition comprising an ige antibody
GB201919062D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody
GB201902590D0 (en) Antibodies and uses thereof
GB202309981D0 (en) Antibody
IL290570A (en) Anti-cd19 antibodies and their use
AU2021401712A9 (en) Antibody composition
IL288807A (en) Anti-talen antibodies and their uses